William Blair Analysts Lift Earnings Estimates for CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics AG (NASDAQ:CRSP) – William Blair lifted their Q3 2024 earnings estimates for shares of CRISPR Therapeutics in a research note issued on Tuesday, August 6th. William Blair analyst S. Corwin now anticipates that the company will post earnings of ($1.18) per share for the quarter, up from their prior forecast of ($1.26). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.52) per share. William Blair also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($0.63) EPS, FY2024 earnings at ($4.68) EPS, Q1 2025 earnings at ($1.29) EPS, Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($0.92) EPS and FY2025 earnings at ($4.42) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. The business’s revenue was down 99.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.98) earnings per share.

Other equities analysts also recently issued reports about the stock. Barclays lowered their price objective on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating for the company in a research note on Tuesday. Stifel Nicolaus reduced their price target on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday. Guggenheim reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Friday, June 28th. Piper Sandler reiterated an “overweight” rating and set a $105.00 price target on shares of CRISPR Therapeutics in a research report on Monday, June 17th. Finally, Robert W. Baird upped their price objective on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $74.00.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock traded down $0.85 during mid-day trading on Thursday, hitting $47.01. The company’s stock had a trading volume of 998,709 shares, compared to its average volume of 1,596,176. The stock has a market cap of $3.99 billion, a price-to-earnings ratio of -17.28 and a beta of 1.70. The business has a 50 day moving average price of $56.72 and a 200-day moving average price of $62.88. CRISPR Therapeutics has a 12 month low of $37.55 and a 12 month high of $91.10.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CRSP. Capital International Investors lifted its holdings in shares of CRISPR Therapeutics by 27.8% in the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after acquiring an additional 1,702,624 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of CRISPR Therapeutics by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock worth $111,564,000 after acquiring an additional 46,148 shares during the last quarter. SR One Capital Management LP bought a new stake in shares of CRISPR Therapeutics in the 1st quarter worth about $71,496,000. Dimensional Fund Advisors LP lifted its holdings in shares of CRISPR Therapeutics by 2.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock worth $51,326,000 after acquiring an additional 19,094 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of CRISPR Therapeutics by 2.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 653,023 shares of the company’s stock worth $40,879,000 after acquiring an additional 15,085 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 3,366 shares of the firm’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at $378,327.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.